Semaglutide Significantly Reduces Alcohol Drinking in Primates That Prefer Alcohol

This was a vehicle-controlled study in 20 male African green monkeys with demonstrated alcohol preference. After 10 days of baseline alcohol consumption measurement (4 hours daily access), monkeys were randomized to semaglutide (n=10) or vehicle (n=10), balanced for baseline alcohol intake. Semaglutide was escalated to 0.05 mg/kg over 2 weeks (without alcohol access), then maintained for 3 weeks during which alcohol consumption was measured over 20 days. A 1-week washout period followed. Alcohol intake, water intake, and emetic events were monitored.

Alcohol use disorder affects hundreds of millions of people worldwide and current treatments have limited efficacy. The observation that GLP-1 drugs might reduce alcohol consumption has generated enormous clinical interest, but the evidence has been largely from rodent studies and anecdotal human reports. Non-human primates are much closer to humans in brain structure and reward circuitry, so this primate demonstration significantly strengthens the case for clinical trials of semaglutide in alcohol use disorder.

This study sits at the convergence of two major pharmaceutical trends: the explosive growth of GLP-1 receptor agonists and the desperate need for better alcohol addiction treatments. If semaglutide proves effective for alcohol use disorder in clinical trials, it would represent a paradigm shift — potentially treating obesity, diabetes, and addiction with a single medication. Multiple human clinical trials are now underway based on the growing preclinical and anecdotal evidence, and this primate study provides crucial translational support.

The study used only male monkeys (n=10 per group), so results may not apply to females. The 4-week treatment period is short relative to the chronic nature of alcohol use disorder. The dose (0.05 mg/kg twice weekly) may not directly translate to human clinical dosing. While the monkeys preferred alcohol, they were not alcohol-dependent in the clinical sense — they didn't experience withdrawal or compulsive drinking. The study cannot determine whether semaglutide's effect would persist long-term or whether alcohol consumption would rebound after stopping treatment.